Drugs / Spectrila®
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Spectrila | — | 2016-01-14 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03156790 | Apr 2019 → Nov 2025 | B-cell acute lymphoblastic leukemia | medac GmbH | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spectrila | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03156790 ↗ |
| Modality | Protein / enzyme biologic | “recombinant L-Asparaginase” NCT03156790 ↗ |
| Route | Intravenous | “3 intravenous doses of 10 000 U/m² BSA each” NCT03156790 ↗ |